Intensity Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Intensity Therapeutics is a clinical-stage biotechnology company developing intratumoral cancer treatments; it has not generated revenue from product sales or licensing. Its lead candidate, INT230-6, combines cisplatin and vinblastine sulfate with an amphiphilic molecule for direct injection into tumors.
Financial performance and liquidity
- Revenue: None. The company does not expect product revenue in the foreseeable future.
- Operating expenses: $4.743 million, up $3.489 million (about 278%) from $1.254 million in Q1 2023. Research and development was $2.815 million versus $0.774 million; general and administrative was $1.928 million versus $0.480 million.
- Net loss: $4.603 million, compared with $1.336 million a year earlier. Basic and diluted loss per share was $0.34, versus $0.39; weighted-average shares rose to 13.71 million from 3.41 million.
- Cash flow: Cash used in operations was $4.366 million, compared with $0.901 million in Q1 2023. The company redeemed $3.260 million of marketable securities and received $8,000 from warrant exercises. Cash and cash equivalents declined $1.098 million to $7.458 million.
- Balance sheet at March 31: Cash, cash equivalents and marketable debt securities totaled $10.497 million, down from $14.776 million at December 31, 2023. Total assets were $12.408 million; total liabilities were $2.686 million; stockholders’ equity was $9.722 million. No convertible notes were outstanding; lease liabilities totaled $157,000.
- Margins and debt: Margins are not meaningful because the company had no revenue. The filing reports no outstanding convertible notes or other borrowings; lease obligations remain.
Material changes and operating developments
- R&D expense increased primarily from preliminary work for the planned INVINCIBLE-3 sarcoma study, higher clinical-trial activity, and a new INT230-6 manufacturing batch.
- G&A expense rose with higher stock-based compensation, public-company costs, insurance, and staffing, including the hiring of a CFO in Q4 2023.
- Stock-based compensation increased to $1.155 million from $312,000. Common shares outstanding were 13,711,877 at March 31, 2024.
- The company reported prior INVINCIBLE-2 Phase 2 breast-cancer study results showing favorable safety, substantial tumor necrosis in some patients, and immune-cell and T-cell-repertoire changes. These are company-reported clinical findings, not proof of approved or established efficacy.
Outlook, risks and contingencies
- Management expected to begin the Phase 3, open-label, randomized INVINCIBLE-3 study in certain soft tissue sarcoma subtypes in mid-2024, planning to enroll 333 patients with overall survival as the endpoint. More than 30 sites had been screened and qualified, with site contracting and activation still underway.
- Management also planned to initiate the INVINCIBLE-4 Phase 2/3 program in triple-negative breast cancer in mid-2024. The Phase 2 portion is intended to assess pathological complete response and inform Phase 3 sizing.
- Management estimated that cash and investments would fund the current operating plan through the end of Q1 2025. The company has no committed external funding source, expects substantial future losses, and disclosed substantial doubt about its ability to continue as a going concern. Additional financing may dilute shareholders or may not be available; without funding, trials or development could be delayed, reduced, or terminated.
- In May 2024, after quarter-end, the company agreed to fund a European Phase 2 randomized early-stage breast-cancer study, with aggregate payments of up to $3.0 million over several years subject to milestones.
- Disclosure controls and procedures were not effective at March 31 due to material weaknesses involving segregation of duties, review and reconciliation of clinical contract accruals, and IT user access. Remediation was underway, but the company could not assure full remediation.
- The company said its risk factors had not materially changed from its 2023 Form 10-K. It also noted potential loss of a Russian patent if future payments are restricted and that an Israeli patent is in a location affected by military action. No material adverse legal proceedings were reported.
Most important facts for investors to verify
- Whether the planned INVINCIBLE-3 and INVINCIBLE-4 studies started on schedule, and the resulting costs, enrollment pace, and clinical milestones.
- Whether the stated runway through Q1 2025 remains realistic given operating cash use and the additional study commitment of up to $3.0 million.
- Availability, timing, and terms of any additional financing, including potential dilution.
- Progress and evidence supporting INT230-6’s safety and efficacy, including whether results are replicated in larger controlled studies.
- Remediation of the disclosed material weaknesses and effectiveness of financial reporting controls.